Eli Lilly announced its second-quarter earnings report on Wednesday. Profits and revenue surged significantly beyond market expectations and raised sales guidance for the full year. Demand for its popular weight loss drug Zepbound and the diabetes drug Mounjaro surged again. The pharmaceutical giant currently expects revenue of between $85 billion and $87 billion in 2026, compared to the previous guidance of $82 billion to $85 billion. Eli Lilly expects full-year adjusted earnings of $35.50‑36.50 per share, compared to $35.50‑37. The company said that the median value of the underlying profit guide increased by $2.78 per share, but the total fees associated with multiple transactions this quarter were offset by a total of $3.03 per share. Thanks to huge profits from obesity and diabetes medications, Eli Lilly is beginning a round of large-scale mergers and acquisitions. The company just reached a deal to acquire a hallucinogenic drug company in July, and also announced plans to acquire three vaccine companies in May. Despite a drop in the price of these two drugs in the US market, demand for Zepbound and Mounjaro remains strong, supporting Eli Lilly's positive results for several consecutive quarters. Mounjaro's global revenue for the quarter increased 91% to $9.94 billion, including sales in the US market of $4.8 billion. According to StreetAccount data, this figure is higher than analysts' previous expectations for global sales of $8.99 billion and US market revenue of $4.44 billion. Mounjaro performed particularly well in overseas markets, with sales outside the US soaring 172%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.